MARKET

ANGO

ANGO

Angiodynamics
NASDAQ
6.31
-0.06
-0.94%
After Hours: 6.31 0 0.00% 16:17 04/15 EDT
OPEN
6.41
PREV CLOSE
6.37
HIGH
6.42
LOW
6.25
VOLUME
596.54K
TURNOVER
0
52 WEEK HIGH
11.38
52 WEEK LOW
5.26
MARKET CAP
252.74M
P/E (TTM)
-1.3195
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ANGO last week (0408-0412)?
Weekly Report · 1d ago
AngioDynamics CEO, President & Director Acquires 2.6% More Stock
AngioDynamics, Inc. CEO, President & Director, James Clemmer, recently bought US$67k worth of stock. The recent purchase is a good sign for shareholders of the company. In the last year, AngioDynamicics insiders have purchased US$6.70 worth of shares. The company didn't make a profit in the last 12 months. It's good to see an insider purchase at close to current prices. But the company does not have a high level of insider ownership. Angiodynamics owns 2.9% of Angio dynamics.
Simply Wall St · 3d ago
AngioDynamics, Inc. Quarterly Report for the Period Ended February 29, 2024
Press release · 6d ago
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. Recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable Angiodynamics.
Seeking Alpha · 6d ago
Insiders Buying Zumiez And 3 Other Stocks
U.S. Stocks closed little changed on Monday. There were a few notable insider trades. Insider purchases indicate confidence in the company's prospects or that they view the stock as a bargain. AngioDynamics, Inc. And Zumiez Inc. Made recent notable insider purchases.
Benzinga · 04/09 11:29
Weekly Report: what happened at ANGO last week (0401-0405)?
Weekly Report · 04/08 09:28
AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
AngioDynamics, Inc. Shares have gained 26% in the last month but are still down 26% over the last year. The company's price-to-sales ratio of 0.9x is still low compared to its industry peers. Its revenue growth is expected to lag the industry in the coming years. Despite this, the company's P/S is still a strong buying opportunity for investors.
Simply Wall St · 04/06 13:28
Buy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth Opportunities
Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on AngioDynamics (ANGO – Research Report) The company has reported a significant increase in pro forma revenue. Chen is an analyst with an average return of -21.7% and a 29.59% success rate.
TipRanks · 04/05 16:25
More
About ANGO
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

Webull offers AngioDynamics, Inc. stock information, including NASDAQ: ANGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANGO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANGO stock methods without spending real money on the virtual paper trading platform.